Clinical Trials Logo

Clinical Trial Summary

The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation. Nowadays there is no effective way to salvage patients in such conditions. T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability, which makes it serve well for patients with relapsed B-ALL. So we launched a multi-center clinical trial to proved the safety and efficacy of anti-CD19 CAR-T cells for relapsed B cell ALL.


Clinical Trial Description

The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies. However, for B-ALL patients suffered from relapse after allo-HSCT (hematopoietic stem cell transplant), the T cells derived from healthy donor seems like a better origin for CAR-T cells producing because T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability. So after we designed a clinical trial to manifest the safety and efficacy of anti-CD19 CAR-T cells for patients with relapsed B cell ALL. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04516551
Study type Interventional
Source Xinqiao Hospital of Chongqing
Contact Xi Zhang, MD phD
Phone 13808310064
Email zhangxxi@sina.com
Status Recruiting
Phase Phase 1
Start date November 20, 2020
Completion date December 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03463928 - A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia Phase 1
Active, not recruiting NCT01683279 - A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT03383952 - A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia Phase 1
Recruiting NCT03166878 - A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Phase 1/Phase 2
Recruiting NCT04747093 - Induced-T Cell Like NK Cells for B Cell Malignancies Phase 1/Phase 2
Recruiting NCT03398967 - A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma Phase 1/Phase 2
Recruiting NCT03881774 - Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies Phase 1
Recruiting NCT04156243 - CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies Early Phase 1
Active, not recruiting NCT03302403 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors N/A
Completed NCT01626495 - Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma Phase 1/Phase 2
Recruiting NCT04156178 - CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies Early Phase 1
Not yet recruiting NCT05779930 - Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL Early Phase 1
Completed NCT02132624 - CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. Phase 1/Phase 2
Completed NCT05095155 - Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality